TW1 <GO>TARGET WATCH2 <GO>MARKETLIVE
API

Bavarian Nordic

Latest price
207.40 DKK
17/09/2026
Latest (4)
281.25 DKK
+35.61%
Upside
Aligned
AVG (4)
280.00 DKK
+35.00%
Upside
Aligned
BAVA
3 mo+35.00%4 price targets
6 mo+35.00%4 price targets
1 yr+31.39%6 price targets
Max 7 price targets
SEBDNB CarnegieDanske BankNordea
HealthcareBiotechnology

About The Company

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Yahoo Finance

Latest Consensus

The average of the latest price targets from multiple analysts.

Consensus
281.25 DKK
Upside
+35.61%
Aligned4 houses · range 265.00 DKK–300.00 DKK
265.00 DKK300.00 DKK

line = latest price · dot = consensus

Latest price207.40 DKK

Three Month Consensus

The median of each house's latest target set within the last 90 days.

Consensus
280.00 DKK
Upside
+35.00%
Aligned4 houses · range 265.00 DKK–300.00 DKK · last 90 days
265.00 DKK300.00 DKK

line = latest price · dot = consensus

Latest price207.40 DKK

More Price Targets for Bavarian Nordic

Analyst
Hit rate 62 %
Date
Aug 24

Analyst
Hit rate 51 %
Date
Aug 24

Analyst
Hit rate 56 %
Date
Aug 24

Analyst
Hit rate 57 %
Date
Aug 24

Analyst
Date
Feb 20

Analyst
Hit rate 63 %
Date
Feb 3

Analyst
Date
Aug -25